Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN WILLIAM SWISHER

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1083609564
CMS profile
140115
Location
KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$26,314.79

77 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN WILLIAM SWISHER

NPI 1083609564 · CMS profile ID 140115

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083609564?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN WILLIAM SWISHER, NPI 1083609564, CMS profile ID 140115. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083609564?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JOHN WILLIAM SWISHER, NPI 1083609564, CMS profile ID 140115. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083609564?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JOHN WILLIAM SWISHER, NPI 1083609564, CMS profile ID 140115, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1083609564?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

77 matching records · $26,314.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 77 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–77 of 77.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $15.0005/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915697359 CMS
United Therapeutics Corporation $922.5005/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957940113 CMS
Actelion Pharmaceuticals US, Inc. $24.3905/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885416147 CMS
United Therapeutics Corporation $100.0005/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957940109 CMS
United Therapeutics Corporation $3,400.0005/03/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957940111 CMS
United Therapeutics Corporation $3,400.0005/02/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957940107 CMS
Actelion Pharmaceuticals US, Inc. $17.5204/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885416161 CMS
Actelion Pharmaceuticals US, Inc. $18.2004/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885416153 CMS
United Therapeutics Corporation $1,127.5004/22/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957940103 CMS
United Therapeutics Corporation $922.5004/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957940101 CMS
AstraZeneca Pharmaceuticals LP $76.7904/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914728245 CMS
Actelion Pharmaceuticals US, Inc. $7.9404/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885416155 CMS
Actelion Pharmaceuticals US, Inc. $14.0404/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885416157 CMS
Actelion Pharmaceuticals US, Inc. $2.5004/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885416159 CMS
United Therapeutics Corporation $102.5004/01/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957940099 CMS
Alexion Pharmaceuticals, Inc. $18.9703/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914781137 CMS
Actelion Pharmaceuticals US, Inc. $18.1903/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885416165 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.0803/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955846873 CMS
Gilead Sciences, Inc. $14.8603/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929534851 CMS
PFIZER INC. $14.5503/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949099623 CMS
Actelion Pharmaceuticals US, Inc. $13.3502/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885416167 CMS
United Therapeutics Corporation $97.0002/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957960449 CMS
United Therapeutics Corporation $15.0002/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957960471 CMS
Actelion Pharmaceuticals US, Inc. $2.1501/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885416177 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.9001/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955846869 CMS
Actelion Pharmaceuticals US, Inc. $16.0301/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885416163 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.5401/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887769307 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $15,535.90 64
PY2020 $9,941.87 37
PY2021 $10,400.15 41
PY2022 $26,314.79 77
PY2023 $44,492.79 94
PY2024 $71,855.08 160
PY2025 $55,294.81 141

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $445,894.55 13
PY2024 Principal investigator $522,538.28 16
PY2023 Principal investigator $478,491.48 12
PY2022 Principal investigator $483,899.04 19
PY2021 Principal investigator $5,616.29 6
PY2020 Principal investigator $62,104.15 38
PY2019 Principal investigator $93,270.51 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

13 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $38,914.81 12/31/2025 Non-covered Recipient Entity
Statcare Pulmonary Consultants - Knoxville
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension PAH World Health Organization WHO Functional Class FC III o No dispute reported 06/30/2026 1232917567
Principal investigator 1 Merck Sharp & Dohme LLC $28,028.29 12/31/2025 Non-covered Recipient Entity
Statcare Pulmonary Consultants
A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection Fraction HFpEF No dispute reported 06/30/2026 1232938306
Principal investigator 1 Merck Sharp & Dohme LLC $6,209.24 12/31/2025 Non-covered Recipient Entity
Statcare Pulmonary Consultants
A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection Fraction HFpEF No dispute reported 06/30/2026 1232938308
Principal investigator 1 Merck Sharp & Dohme LLC $270,179.19 12/31/2025 Non-covered Recipient Entity
Statcare Pulmonary Consultants - Knoxville
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection F No dispute reported 06/30/2026 1232938644
Principal investigator 1 United Therapeutics Corporation $1,115.00 12/18/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242384607
Principal investigator 1 Merck Sharp & Dohme LLC $48,702.50 12/10/2025 Non-covered Recipient Entity
Statcare Pulmonary Consultants
A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection Fraction HFpEF No dispute reported 06/30/2026 1232938304
Principal investigator 1 Merck Sharp & Dohme LLC $7,900.00 11/24/2025 Non-covered Recipient Entity
Statcare Pulmonary Consultants
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH MK-7962-038 No dispute reported 06/30/2026 1232934024
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,720.00 11/03/2025 Non-covered Recipient Entity
STATCARE PULMONARY
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of LTP001 in Healthy Adult Participants (Part A) and to Evaluate the Efficacy and Safety of LTP001 for th No dispute reported 06/30/2026 1190304289
Principal investigator 1 Merck Sharp & Dohme LLC $991.44 08/27/2025 Non-covered Recipient Entity
Statcare Pulmonary Consultants - Knoxville
An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH No dispute reported 06/30/2026 1232917673
Principal investigator 1 United Therapeutics Corporation $2,410.00 07/16/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242384611
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,900.00 06/27/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH, INC
Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185545049
Principal investigator 1 Merck Sharp & Dohme LLC $3,079.08 05/30/2025 Non-covered Recipient Entity
Statcare Pulmonary Consultants - Knoxville
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection F No dispute reported 06/30/2026 1232938646
Principal investigator 1 United Therapeutics Corporation $1,745.00 05/14/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242384609